All Stories

  1. Using AST-platelet ratio index and fibrosis 4 index for detecting chronic hepatitis C in a large-scale community screening

    Article • PLoS ONE, October 2019, PLOS

    Professor Sheng-Nan Lu

  2. Editorial: hepatitis B, fatty liver and metabolic syndrome-Interaction or co-existence? Authors’ reply

    Article • Alimentary Pharmacology & Therapeutics, October 2018, Wiley

    Professor Sheng-Nan Lu

  3. Association between chronic viral hepatitis and metabolic syndrome in southern Taiwan: a large population-based study

    Article • Alimentary Pharmacology & Therapeutics, September 2018, Wiley

    Professor Sheng-Nan Lu, Dr Jing-Houng Wang, Professor Chang-chun Hsiao

  4. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy

    Article • Journal of Gastroenterology and Hepatology, July 2018, Wiley

    Professor Sheng-Nan Lu, Dr Jing-Houng Wang

  5. A combination of the on-treatment FIB-4 and alpha-foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir

    Article • Liver International, June 2018, Wiley

    Professor Sheng-Nan Lu, Dr Jing-Houng Wang

  6. Role of hepatitis B surface antigen in hepatitis B virus relapse after entecavir or tenofovir prophylaxis in patients undergoing cancer chemotherapy

    Article • Journal of Gastroenterology and Hepatology, April 2018, Wiley

    Professor Sheng-Nan Lu, Dr Jing-Houng Wang

  7. Human leukocyte antigen variants and risk of hepatocellular carcinoma modified by hepatitis C virus genotypes: A genome-wide association study

    Article • Hepatology, January 2018, Wiley

    Professor Sheng-Nan Lu

  8. The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients

    Article • Liver International, December 2017, Wiley

    Professor Sheng-Nan Lu, Dr Jing-Houng Wang

  9. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use

    Article • Journal of Gastroenterology and Hepatology, November 2017, Wiley

    Professor Sheng-Nan Lu, Dr Jing-Houng Wang

  10. Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study

    Article • Hepatology, July 2017, Wiley

    Professor Sheng-Nan Lu

  11. Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy

    Article • Journal of Viral Hepatitis, February 2017, Wiley

    Professor Sheng-Nan Lu, Dr Jing-Houng Wang

  12. Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis

    Article • Journal of Gastroenterology and Hepatology, November 2016, Wiley

    Professor Sheng-Nan Lu

  13. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy

    Article • Liver International, June 2016, Wiley

    Professor Sheng-Nan Lu

  14. Sorafenib achieves complete response of advance HCC

    Article • OncoTargets and Therapy, May 2014, Dove Medical Press

    Dr Jing-Houng Wang, Professor Sheng-Nan Lu